Walleye Capital’s Intensity Therapeutics INTS Stock Holding History

Walleye Capital’s Portfolio INTS Stock Details INTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,135	Closed	-$169K	–	5085
2023 Q2	$169K	Buy	+1,135	New	+$169K	﹤0.01%	3181

Other funds holding INTS

HWM

Hohimer Wealth Management Seattle, Washington $847M AUM 29.89% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

GWS

Glassman Wealth Services Vienna, Virginia $736M AUM 17.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's INTS Position: Q3 2023 in Review

Walleye Capital sold out of Intensity Therapeutics (INTS) in Q3 2023, closing a stake of 1,135 shares — an estimated $169K sold.

Walleye Capital first reported a position in INTS in Q2 2023 and held it in 1 quarter. The position peaked at $169K in Q2 2023. 9 funds tracked by Wall St. Rank hold INTS as of Q3 2023.

Walleye Capital reported no remaining Intensity Therapeutics position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 1,135 Intensity Therapeutics shares in Q3 2023, an estimated $169K.
Walleye Capital first reported a position in Intensity Therapeutics in Q2 2023 and held it in 1 quarter.
Walleye Capital's Intensity Therapeutics position peaked at $169K in Q2 2023.
9 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.